financetom
AMRC
financetom
/
Industrials
/
AMRC
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Ameresco, Inc.AMRC
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Ameresco, Inc., a clean technology integrator, provides a portfolio of energy efficiency and renewable energy supply solutions in the United States, Canada, and internationally.

The company operates through U.S. Regions, U.S. Federal, Canada, and Alternative Fuels segments. It offers energy efficiency, infrastructure upgrades, energy security and resilience, asset sustainability, and renewable energy solutions for businesses and organizations.

It designs, develops, engineers, and installs projects that reduce the energy, as well as operations and maintenance (O&M) costs of its customers' facilities.

The company's projects primarily include various measures customized for the facility and designed to enhance the efficiency of building systems, such as heating, ventilation, cooling, and lighting systems.

It also offers renewable energy solutions and services, such as the construction of small-scale plants that the company owns or develops for customers that produce electricity, gas, heat, or cooling from renewable sources of energy and O&M services; and electricity, processed renewable gas fuel, and heat or cooling produced from renewable sources of energy.

In addition, the company sells photovoltaic (PV) solar energy products and systems, as well as provides consulting and enterprise energy management services; and owns and operates a wind power project.

It serves the federal, state, and local governments, as well as healthcare and educational institutions, airports, public housing authorities and public universities, and commercial and industrial customers.

As of December 31, 2022, the company owned and operated 162 small-scale renewable energy plants and solar PV installations.

Ameresco, Inc. was incorporated in 2000 and is headquartered in Framingham, Massachusetts.

Latest News >
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Market Chatter: Toyota to Partly Compensate Suppliers Hurt by Cancellation of Lexus EV
Jul 2, 2026
06:09 AM EDT, 07/02/2026 (MT Newswires) -- Toyota Motor ( TM ) will partially cover losses worth tens of billions of yen for suppliers affected by its decision to cancel the development of an electric vehicle, Nikkei Asia reported Wednesday. The cancellation of Lexus' LF-ZC sedan has hurt the company's supply chain, with some suppliers likely facing losses of up...
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Nip Group Insider Sold Shares Worth $442,030, According to a Recent SEC Filing
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Liwei Sun, Director, President, on June 30, 2026, sold 353,624 shares in Nip Group ( NIPG ) for $442,030. Following the Form 4 filing with the SEC, Sun has control over a total of 18,095,424 Class B1 ordinary shares of the company, with 18,095,424 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1966233/000149315226031618/xslF345X05/ownership.xml ...
Argentina power firm Genneia files for US IPO
Argentina power firm Genneia files for US IPO
Jul 2, 2026
July 2 (Reuters) - Argentine power producer Genneia filed for an initial public offering in the U.S. on Thursday. (Reporting by Arasu Kannagi Basil in Bengaluru; Editing by Joyjeet Das) ...
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
HUTCHMED's Orpathys Wins Conditional China Approval for Advanced Gastric Cancer
Jul 2, 2026
06:16 AM EDT, 07/02/2026 (MT Newswires) -- Hutchmed ( HCM ) said Thursday China's National Medical Products Administration granted conditional approval to marketing application of its therapy, Orpathys, to treat certain patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The company said the approval is based on a phase 2 study in which Orpathys achieved its primary...
Copyright 2023-2026 - www.financetom.com All Rights Reserved